Paul Resnick, Vice President and Chief Business Officer at MabVax Therapeutics
MabVax Therapeutics Logo

Paul Resnick


Vice President and Chief Business Officer
MabVax Therapeutics

Check out the incredible speaker line-up to see who will be joining Paul.

Download The Latest Agenda

The Latest Trends in Biopharma Partnering

Thursday, January 5th, 2017


09:00 Therapeutic Focus Area Ice Breaker Roundtables

Kick-start your partnering experience meeting those who prioritize the same therapeutic areas as you! Find out the latest priorities in the biggest therapeutic areas and current opportunities available. Discuss goals, common industry challenges and firm up your personal partnering objectives for the next three days.

#1 Oncology
Todd Haim, Program Director, NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

#2 Immunology

Kia Motesharei, Head, Global Licensing & Business Development, Immunology, Merck KGaA, Darmstadt, Germany

#3 Immuno-oncology

Paul Resnick, Vice President and Chief Business Officer, MabVax Therapeutics, Inc.

#4 Rare and Orphan Diseases
Joe Whalen, Senior Vice President, Business Development & Alliance Management, Horizon Pharma

#5 Pain
Kathryn Gregory, Executive Director, Business Development, Purdue Pharma

#6 Gene Therapy
Jeremy Ahouse, Executive Director, Business Development & Global Alliances, Celgene

#7 Diabetes
Christoph Pittius, Vice President, Head of Transactions, AstraZeneca

#8
Neurodegenerative Diseases

09:50 Panel Discussion | Going beyond PD-1 and PD-L1, Future Opportunities in Immunotherapies

• What are the latest opportunities for immunology in areas such as cell therapy?
• Just how many immunotherapies can you put checkpoints on top of?
• What are the newest opportunities for combination therapies in immunology?